Petrus J de Vries Selected Research

MTOR Inhibitors

3/2019	[Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
1/2019	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry.
8/2017	mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus.
1/2016	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
7/2015	Neurological and neuropsychiatric aspects of tuberous sclerosis complex.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Petrus J de Vries Research Topics

Disease

49	Tuberous Sclerosis (Bourneville's Disease) 01/2022 - 02/2007
16	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 02/2007
13	Seizures (Absence Seizure) 12/2021 - 08/2007
10	Angiomyolipoma 01/2020 - 06/2011
8	Epilepsy (Aura) 12/2021 - 05/2011
8	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 01/2013
7	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 01/2019 - 01/2008
3	Autism Spectrum Disorder 01/2021 - 01/2014
2	Neoplasms (Cancer) 01/2021 - 01/2016
2	Rare Diseases (Rare Disease) 01/2021 - 11/2014
2	Infantile Spasms (West Syndrome) 01/2021 - 03/2019
2	Hemorrhage 01/2017 - 01/2016
2	Stomatitis 03/2013 - 01/2013
2	Neurofibromatosis 1 (Neurofibromatosis Type I) 05/2011 - 07/2010
1	Neurologic Manifestations (Neurological Manifestations) 01/2021
1	Hypertension (High Blood Pressure) 01/2020
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2020
1	Autistic Disorder (Autism) 08/2017
1	Rhabdomyoma 01/2017
1	Flank Pain 01/2017
1	Angiofibroma 01/2017
1	Hydrocephalus (Hydrocephaly) 01/2016
1	Disease Progression 03/2013
1	Nasopharyngitis 03/2013
1	Acne Vulgaris 03/2013
1	Fever (Fevers) 01/2013
1	LEOPARD Syndrome (Syndrome, LEOPARD) 05/2011
1	Status Epilepticus (Complex Partial Status Epilepticus) 05/2011
1	Tuberous Sclerosis 1 06/2010
1	Intellectual Disability (Idiocy) 02/2007

Drug/Important Bio-Agent (IBA)

40	trans-sodium crocetinate (crocetin)IBA 01/2022 - 02/2007
14	Everolimus FDA Link 12/2021 - 01/2013
9	TOR Serine-Threonine KinasesIBA 01/2021 - 05/2011
5	MTOR InhibitorsIBA 03/2019 - 07/2015
5	Proteins (Proteins, Gene)FDA Link 12/2015 - 08/2007
4	Sirolimus (Rapamycin)FDA Link 03/2013 - 01/2008
3	lipoarabinomannan (LAM)IBA 01/2019 - 06/2011
2	Anticonvulsants (Antiepileptic Drugs)IBA 01/2018 - 10/2016
2	Tuberous Sclerosis Complex 2 ProteinIBA 06/2010 - 08/2007
1	Vigabatrin FDA Link 01/2021
1	SteroidsIBA 01/2021
1	gamma-Aminobutyric Acid (GABA)IBA 03/2019
1	Aminobutyrates (Aminobutyric Acid)IBA 03/2019
1	adriamycin-14-valerate (AD 48)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Mechanistic Target of Rapamycin Complex 1IBA 06/2011
1	Kainic Acid (Kainate)IBA 05/2011
1	TensinsIBA 07/2010
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 07/2010
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2010
1	Tuberous Sclerosis Complex 1 ProteinIBA 08/2007

Therapy/Procedure

7	Therapeutics 12/2021 - 01/2008
1	Nephrectomy 01/2017